Tepmetko for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations
Quick answer: Tepmetko is used for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations as part of a met tyrosine kinase inhibitor treatment regimen. Brand name for tepotinib; selective inhibitor of MET receptor tyrosine kinase blocking tumor cell proliferation in MET-altered cancers The specific dosing for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations is determined by your prescriber based on individual factors.
Why is Tepmetko used for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations?
Tepmetko belongs to the MET tyrosine kinase inhibitor class. Brand name for tepotinib; selective inhibitor of MET receptor tyrosine kinase blocking tumor cell proliferation in MET-altered cancers This action makes it useful for treating or managing Metastatic non-small cell lung cancer with MET exon 14 skipping alterations in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Tepmetko is the right choice for a specific patient depends on the type and severity of Metastatic non-small cell lung cancer with MET exon 14 skipping alterations, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations
Common adult dosing range: 450 mg once daily. The actual dose for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Tepmetko medicine page.
What to expect
Tepmetko treatment for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Metastatic non-small cell lung cancer with MET exon 14 skipping alterations
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Tepmetko is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all MET tyrosine kinase inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Tepmetko
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Tepmetko full prescribing information · All MET tyrosine kinase inhibitor alternatives
Frequently asked questions
How effective is Tepmetko for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations?
Effectiveness varies by individual response, dose, and severity. Tepmetko is one of several treatment options for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations, supported by clinical evidence within the met tyrosine kinase inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Tepmetko for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations?
Treatment duration depends on the nature of Metastatic non-small cell lung cancer with MET exon 14 skipping alterations — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Tepmetko when used for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Tepmetko for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations?
Yes. Multiple medicines and non-drug options exist for Metastatic non-small cell lung cancer with MET exon 14 skipping alterations. Alternatives within the met tyrosine kinase inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.